FPP 003
Alternative Names: FPP-003; IL17A vaccine - FunPepLatest Information Update: 25 Sep 2025
At a glance
- Originator FunPep; Osaka University School of Medicine
- Class Anti-inflammatories; Antipsoriatics; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ankylosing spondylitis
- Phase I/II Psoriasis
Most Recent Events
- 25 Sep 2025 Phase-II clinical trials in Ankylosing spondylitis in Japan (SC) (FunPep pipeline, September 2025)
- 12 Jun 2024 Immunogenicity and adverse events data from a phase I trial in Ankylosing spondylitis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 18 Jul 2023 Phase-I clinical trials in Ankylosing spondylitis in Japan (SC) (FunPep pipeline, July 2023)